Javascript must be enabled to continue!
Human DND1-RRM2 forms a non-canonical domain swapped dimer
View through CrossRef
Summary
Human DND1 (Dead end protein homolog1) is an RNA binding protein. DND1 plays pivotal role in animal development and has been implicated in cancer. DND1 consists of two RNA recognition motifs (RRMs) in tandem and a double stranded RNA binding domain at the C terminal separated by 40 residues flexible linker. The conserved RNP site in the RRM1 domain helps in specific RNA recognition while the RNP sites in RRM2 are not well conserved. DND1 has been reported to be involved in inhibition of microRNA access to target mRNA and it also associate with CCR4-NOT complex that targets mRNA. In order to understand this intriguing contrasting molecular function, we have determined the 2.3 Å resolution crystal structure of the human DND1 RRM2 domain. The structure revealed an interesting non-canonical RRM fold that is maintained by the formation of a domain swapped dimer between β
1
and β
4
strands across two chains. The domain swapping is attributed by a hinge loop between α
2
and β
4
that helps in mediating a domain swap forming anti-parallel β sheets. We have delineated the structural basis of stable dimer formation using the residue level dynamics of protein explored by NMR spectroscopy and MD simulations. Our structural and dynamics studies demonstrate the molecular basis for the dimerization of the RRM2 domain and shed light on the possibility for this motif for interaction with other proteins which helps in transcription regulation.
Graphical Abstract
Highlights
First report of a domain swapped dimer formation by an RRM identified through crystal structure determination of the human DND1 RRM2 domain.
RRM2 exhibit domain swapped dimerization attributed by hinge loop and disulfide bond formation.
Dimer formation is under redox regulation.
Major determinants of swapping were identified.
DND1 RRM2 is not involved in RNA recognition.
Title: Human DND1-RRM2 forms a non-canonical domain swapped dimer
Description:
Summary
Human DND1 (Dead end protein homolog1) is an RNA binding protein.
DND1 plays pivotal role in animal development and has been implicated in cancer.
DND1 consists of two RNA recognition motifs (RRMs) in tandem and a double stranded RNA binding domain at the C terminal separated by 40 residues flexible linker.
The conserved RNP site in the RRM1 domain helps in specific RNA recognition while the RNP sites in RRM2 are not well conserved.
DND1 has been reported to be involved in inhibition of microRNA access to target mRNA and it also associate with CCR4-NOT complex that targets mRNA.
In order to understand this intriguing contrasting molecular function, we have determined the 2.
3 Å resolution crystal structure of the human DND1 RRM2 domain.
The structure revealed an interesting non-canonical RRM fold that is maintained by the formation of a domain swapped dimer between β
1
and β
4
strands across two chains.
The domain swapping is attributed by a hinge loop between α
2
and β
4
that helps in mediating a domain swap forming anti-parallel β sheets.
We have delineated the structural basis of stable dimer formation using the residue level dynamics of protein explored by NMR spectroscopy and MD simulations.
Our structural and dynamics studies demonstrate the molecular basis for the dimerization of the RRM2 domain and shed light on the possibility for this motif for interaction with other proteins which helps in transcription regulation.
Graphical Abstract
Highlights
First report of a domain swapped dimer formation by an RRM identified through crystal structure determination of the human DND1 RRM2 domain.
RRM2 exhibit domain swapped dimerization attributed by hinge loop and disulfide bond formation.
Dimer formation is under redox regulation.
Major determinants of swapping were identified.
DND1 RRM2 is not involved in RNA recognition.
Related Results
Human
DND1‐RRM2
forms a non‐canonical domain swapped dimer
Human
DND1‐RRM2
forms a non‐canonical domain swapped dimer
Abstract
RNA recognition motif (RRM) being the most abundant RNA binding domain in eukaryotes, is a major player in cellular regulation. Seve...
Interference of Heterophilic Antibody in D-dimer Determination in an Asymptomatic Elderly Woman
Interference of Heterophilic Antibody in D-dimer Determination in an Asymptomatic Elderly Woman
Background: D-Dimer is considered a pivotal biomarker in diagnosis of disseminated intravascular coagulation and in differential diagnosis of thrombosis and pulmonary embolism.
Cas...
D‐dimer in Adolescent Pulmonary Embolism
D‐dimer in Adolescent Pulmonary Embolism
AbstractBackgroundD‐dimer is used to aid in diagnosing adult pulmonary embolism (PE). D‐dimer has not been validated in adolescents. Clinicians must balance the risk of overtesting...
Characteristics and Treatment Outcomes of Acute Type A Aortic Dissection With Elevated D‐Dimer Concentration
Characteristics and Treatment Outcomes of Acute Type A Aortic Dissection With Elevated D‐Dimer Concentration
Background
Clinical characteristics and treatment outcomes of acute type A aortic dissection with D‐dimer elevation have not been clarified.
...
9198 Dimeric [Cys25]PTH(1-34) Induces Differential Transcriptional Responses Versus Monomeric PTH(1-34)
9198 Dimeric [Cys25]PTH(1-34) Induces Differential Transcriptional Responses Versus Monomeric PTH(1-34)
Abstract
Disclosure: M. Noh: None. H.J. Kim: None. J. Kim: None. M. Kang: None. S. Lee: None. H. Lee: None. S. Lee: None.
Introduction: Patients with ...
8279 Dimeric [Cys25]PTH(1-34) Induces Differential Transcriptional Responses Versus Monomeric PTH(1-34)
8279 Dimeric [Cys25]PTH(1-34) Induces Differential Transcriptional Responses Versus Monomeric PTH(1-34)
Abstract
Disclosure: M. Noh: None. H.J. Kim: None. J. Kim: None. M. Kang: None. S. Lee: None. H. Lee: None. S. Lee: None.
Introduction: Patients with ...
Identification of Biomarkers for Prognosis and Immunotherapy in Clear Cell Renal Cell Carcinoma
Identification of Biomarkers for Prognosis and Immunotherapy in Clear Cell Renal Cell Carcinoma
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is the dominating subtype of renal cancer with high malignancy and poor prognosis, accounts for the majority of...
Some indicators of hemostasis and mortality from thrombotic complications in patients with CKD stage VD who were treated by programmed hemodialysis (five-year follow-up)
Some indicators of hemostasis and mortality from thrombotic complications in patients with CKD stage VD who were treated by programmed hemodialysis (five-year follow-up)
Annotation. Thrombotic complications in patients with stage VD chronic kidney disease (CKD), treated by program hemodialysis is one of the causes of high mortality in this category...

